The guidelines still emphasize the importance of preconception counseling and achieving disease remission prior to conception to lower the risk of adverse pregnancy outcomes. Decreased fertility remains an important outcome in post-surgical patients, especially in patients with ileal pouch anal anastomosis.

Since the 2018 guideline, multiple new biologic and small molecule agents have been approved for Crohn’s disease, and data have emerged supporting earlier initiation of advanced therapies to improve long-term outcomes. The 2025 update reflects this shift toward early treat-to-target strategies, the de-implementation of ineffective agents, and individualized therapy selection based on disease phenotype, prior exposures, and patient preferences.

Evidence-based summary of the 2025 ACG updated guidelines for ulcerative colitis. How can healthcare providers manage ulcerative colitis (UC) in adults? What are appropriate therapies for mild-to-moderate disease, moderate-to severe disease and the hospitalized patient?

Bridging the Gap: Impact of Gender-Affirming Care on IBD Flare Rates Hayley Rogers, MD1 and Nikki Duong, MD2 1Advanced Endoscopy…

Subcutaneous Guselkumab Is Effective for Both Induction and Maintenance of Crohn’s Disease Rahul Dalal, MD, MPH  Instructor, Division of Gastroenterology,…

EBGI summary discussed a RCT from the Netherlands that examines neoplasia detection rates in individuals with IBD without active inflammation who were scheduled for endoscopic surveillance randomized to HD white-light endoscopy with segmental reinspection, single-pass HD white-light endoscopy, or to HD chromoendoscopy.

Mirikizumab Is Safe and Effective for Moderate-to-Severe Crohn’s Disease Rahul Dalal, MD, MPH  Instructor, Division of Gastroenterology, Hepatology, and Endoscopy,…

Tofacitinib in Acute Severe Ulcerative Colitis (TACOS): A Randomized Controlled Trial Ellen Axenfeld, MD1 and Elie S. Al Kazzi, MD,…

The Edge of a New Frontier: Anti-TL1A Monoclonal Antibodies for Ulcerative Colitis Maryam Ibrahim, MD1 and Bharati Kochar, MD, MS2…

Subcutaneous Infliximab for Maintenance of IBD Remission: Added Convenience With   Potential for Improved Efficacy? Elie S. Al Kazzi, MD, MPH…